Todd Meyerrose Joins Luventix Advisory Board

Luventix, a leader in Intelligent Disease Diagnostics, is thrilled to announce that Todd Meyerrose, PhD, a distinguished figure in oncology research and biotechnology, has joined its Advisory Board. Dr. Meyerrose brings a wealth of experience in precision medicine, biotechnology innovation, and strategic leadership to Luventix’s mission of revolutionizing healthcare diagnostics.

Dr. Meyerrose is the co-founder of Lexent Bio, a precision oncology company acquired by Foundation Medicine, a Roche subsidiary, in 2020. His pioneering work on liquid biopsy platforms for monitoring minimal residual disease in solid tumors has set a benchmark in cancer diagnostics. With dual PhDs in Craniofacial Biology and Molecular Cell Biology and a postdoctoral fellowship at the Whitehead Institute, Dr. Meyerrose has held key roles including founding Navio, serving as a Founding Partner at BioMed Ventures, and teaching at Stanford University.

"We are honored to welcome Dr. Todd Meyerrose to our Advisory Board," said George Holmes, CEO of Luventix. "His expertise in oncology, diagnostics, and personalized medicine will be instrumental as we advance our innovative solutions and redefine industry standards in healthcare."

About Luventix
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) techniques, Luventix analyzes data to pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment, and enabling companion diagnostics as an integral endpoint.

With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions.

For more information, visit: www.luventix.com.

Media Contact:
ir@luventix.com